Acute Liver Failure: Current Practice and Recent Advances

Gastroenterology Clinics of North America

Volumn 40, Issue 3, 2011, Pages 523-539

  Sundaram, Vinay ^a   Shaikh, Obaid S ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Brain edema; Encephalopathy; Liver transplantation

Indexed keywords

ACETYLCYSTEINE; MANNITOL; PENTOBARBITAL; SODIUM CHLORIDE; THIOPENTAL;

ACUTE LIVER FAILURE; ASSISTED VENTILATION; ASSISTIVE TECHNOLOGY DEVICE; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BLOOD FLOWMETRY; BRAIN BLOOD FLOW; BRAIN EDEMA; CELL TRANSPLANTATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DEVICE THERAPY; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; ELECTROENCEPHALOGRAPHY; HEART HEMODYNAMICS; HUMAN; HYPERVENTILATION; INDUCED HYPOTHERMIA; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE MONITORING; INTRAVENOUS ADMINISTRATION; KIDNEY FAILURE; LIVER SUPPORT; LIVER TRANSPLANTATION; LUNG HEMODYNAMICS; NONHUMAN; PATHOGENESIS; REVIEW; SEIZURE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BLOOD COAGULATION DISORDERS; BRAIN EDEMA; HEPATIC ENCEPHALOPATHY; HEPATOCYTES; HUMANS; HYPERVENTILATION; INFECTION; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; METABOLIC DISEASES; RENAL INSUFFICIENCY; SEIZURES;

EID: 80052343561     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2011.06.009     Document Type: Review

References (126)

1. Polson J., Lee W.M. AASLD position paper: the management of acute liver failure. Hepatology 2005, 41:1179-1197. American Association for the Study of Liver D.
2. Shakil A.O., Jones B.C., Lee R.G., et al. Prognostic value of abdominal CT scanning and hepatic histopathology in patients with acute liver failure. Dig Dis Sci 2000, 45:334-339.
3. Sass D.A., Shakil A.O. Fulminant hepatic failure. Liver Transpl 2005, 11:594-605.
4. Lee W.M., Seremba E. Etiologies of acute liver failure. Curr Opin Crit Care 2008, 14:198-201.
5. Khuroo M.S., Kamili S. Aetiology and prognostic factors in acute liver failure in India. J Viral Hepat 2003, 10:224-231.
6. Sarwar S., Khan A.A., Alam A., et al. Predictors of fatal outcome in fulminant hepatic failure. J Coll Physicians Surg Pak 2006, 16:112-116.
7. Shakil A.O., Kramer D., Mazariegos G.V., et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000, 6:163-169.
8. O'Grady J.G., Schalm S.W., Williams R. Acute liver failure: redefining the syndromes. Lancet 1993, 342:273-275.
9. Blei A.T. Brain edema in acute liver failure. Crit Care Clin 2008, 24:99-114.
10. Jackson E.W., Zacks S., Zinn S., et al. Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: a matched, case-controlled study. Liver Transpl 2002, 8:932-936.
11. Bjerring P.N., Eefsen M., Hansen B.A., et al. The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema. Metab Brain Dis 2009, 24:5-14.
12. Ranjan P., Mishra A.M., Kale R., et al. Cytotoxic edema is responsible for raised intracranial pressure in fulminant hepatic failure: in vivo demonstration using diffusion-weighted MRI in human subjects. Metab Brain Dis 2005, 20:181-192.
13. Wright G., Shawcross D., Olde Damink S.W.M., et al. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis 2007, 22:375-388.
14. Stravitz R.T., Kramer A.H., Davern T., et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007, 35:2498-2508.
15. Blei A.T., Olafsson S., Webster S., et al. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993, 341:157-158.
16. Keays R.T., Alexander G.J., Williams R. The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 1993, 18:205-209.
17. Le T.V., Rumbak M.J., Liu S.S., et al. Insertion of intracranial pressure monitors in fulminant hepatic failure patients: early experience using recombinant factor VII. Neurosurgery 2010, 66:455-458.
18. Vaquero J., Fontana R.J., Larson A.M., et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005, 11:1581-1589.
19. Larsen F.S., Ejlersen E., Hansen B.A., et al. Functional loss of cerebral blood flow autoregulation in patients with fulminant hepatic failure. J Hepatol 1995, 23:212-217.
20. Czosnyka M., Brady K., Reinhard M., et al. Monitoring of cerebrovascular autoregulation: facts, myths, and missing links. Neurocrit Care 2009, 10:373-386.
21. Steiner L.A., Andrews P.J.D. Monitoring the injured brain: ICP and CBF. Br J Anaesth 2006, 97:26-38.
22. Goetting M.G., Preston G. Jugular bulb catheterization: experience with 123 patients. Crit Care Med 1990, 18:1220-1223.
23. Steiner L.A., Coles J.P., Johnston A.J., et al. Assessment of cerebrovascular autoregulation in head-injured patients: a validation study. Stroke 2003, 34:2404-2409.
24. Newell D.W., Aaslid R. Transcranial Doppler: clinical and experimental uses. Cerebrovasc Brain Metab Rev 1992, 4:122-143.
25. Kofke W.A., Brauer P., Policare R., et al. Middle cerebral artery blood flow velocity and stable xenon-enhanced computed tomographic blood flow during balloon test occlusion of the internal carotid artery. Stroke 1995, 26:1603-1606.
26. Aggarwal S., Brooks D.M., Kang Y., et al. Noninvasive monitoring of cerebral perfusion pressure in patients with acute liver failure using transcranial Doppler ultrasonography. Liver Transpl 2008, 14:1048-1057.
27. Torizuka K., Hamamoto K., Morita R., et al. Regional cerebral blood flow measurement with xenon 133 and the scinticamera. Am J Roentgenol Radium Ther Nucl Med 1971, 112:691-700.
28. Gur D., Wolfson S.K., Yonas H., et al. Progress in cerebrovascular disease: local cerebral blood flow by xenon enhanced CT. Stroke 1982, 13:750-758.
29. Durham S., Yonas H., Aggarwal S., et al. Regional cerebral blood flow and CO2 reactivity in fulminant hepatic failure. J Cereb Blood Flow Metab 1995, 15:329-335.
30. Bhatia V., Batra Y., Acharya S.K. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure-a controlled clinical trial. J Hepatol 2004, 41:89-96.
31. Gabor A.J., Brooks A.G., Scobey R.P., et al. Intracranial pressure during epileptic seizures. Electroencephalogr Clin Neurophysiol 1984, 57:497-506.
32. Ellis A.J., Wendon J.A., Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology 2000, 32:536-541.
33. Mascia L., Andrews P.J., McKeating E.G., et al. Cerebral blood flow and metabolism in severe brain injury: the role of pressure autoregulation during cerebral perfusion pressure management. Intensive Care Med 2000, 26:202-205.
34. Ede R.J., Gimson A.E., Bihari D., et al. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986, 2:43-51.
35. Canalese J., Gimson A.E., Davis C., et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982, 23:625-629.
36. Murphy N., Auzinger G., Bernel W., et al. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004, 39:464-470.
37. Tofteng F., Larsen F.S. The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. J Cereb Blood Flow Metab 2004, 24:798-804.
38. Strauss G., Hansen B.A., Knudsen G.M., et al. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. J Hepatol 1998, 28:199-203.
39. Curley G., Kavanagh B.P., Laffey J.G. Hypocapnia and the injured brain: more harm than benefit. Crit Care Med 2010, 38:1348-1359.
40. Neumann J.O., Chambers I.R., Citerio G., et al. The use of hyperventilation therapy after traumatic brain injury in Europe: an analysis of the BrainIT database. Intensive Care Med 2008, 34:1676-1682.
41. Rabinstein A.A. Treatment of brain edema in acute liver failure. Curr Treat Options Neurol 2010, 12:129-141.
42. Diringer M.N., Zazulia A.R. Osmotic therapy: fact and fiction. Neurocrit Care 2004, 1:219-233.
43. Wendon J.A., Harrison P.M., Keays R., et al. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994, 19:1407-1413.
44. Jalan R., Olde Damink S.W., Deutz N.E., et al. Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia. Hepatology 2001, 34:50-54.
45. Marion D.W., Penrod L.E., Kelsey S.F., et al. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med 1997, 336:540-546.
46. Jalan R., Olde Damink S.W., Deutz N.E., et al. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004, 127:1338-1346.
47. Jalan R., O Damink S.W., Deutz N.E., et al. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 1999, 354:1164-1168.
48. Dmello D., Cruz-Flores S., Matuschak G.M. Moderate hypothermia with intracranial pressure monitoring as a therapeutic paradigm for the management of acute liver failure: a systematic review. Intensive Care Med 2010, 36:210-213.
49. Cordoba J., Crespin J., Gottstein J., et al. Mild hypothermia modifies ammonia-induced brain edema in rats after portacaval anastomosis. Gastroenterology 1999, 116:686-693.
50. Qureshi A.I., Suarez J.I. Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension. Crit Care Med 2000, 28:3301-3313.
51. Battison C., Andrews P.J.D., Graham C., et al. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med 2005, 33:196-202.
52. Bulger E.M., May S., Brasel K.J., et al. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA 2010, 304:1455-1464.
53. Toung T.J.K., Chen C.-H., Lin C., et al. Osmotherapy with hypertonic saline attenuates water content in brain and extracerebral organs. Crit Care Med 2007, 35:526-531.
54. Jiang W., Desjardins P., Butterworth R.F. Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline. J Neurochem 2009, 109:485-493.
55. Rhind S.G., Crnko N.T., Baker A.J., et al. Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients. J Neuroinflammation 2010, 7:5.
56. Forbes A., Alexander G.J., O'Grady J.G., et al. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology 1989, 10:306-310.
57. Pernambuco J.R., Langley P.G., Hughes R.D., et al. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 1993, 18:1350-1356.
58. Langley P.G., Williams R. Physiological inhibitors of coagulation in fulminant hepatic failure. Blood Coagul Fibrinolysis 1992, 3:243-247.
59. Langley P.G., Forbes A., Hughes R.D., et al. Thrombin-antithrombin III complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome. Eur J Clin Invest 1990, 20:627-631.
60. Lisman T., Caldwell S.H., Burroughs A.K., et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010, 53:362-371.
61. Gazzard B.G., Henderson J.M., Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975, 16:617-620.
62. Pereira S.P., Rowbotham D., Fitt S., et al. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol 2005, 42:365-370.
63. Shami V.M., Caldwell S.H., Hespenheide E.E., et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003, 9:138-143.
64. Rolando N., Philpott-Howard J., Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis 1996, 16:389-402.
65. Rolando N., Harvey F., Brahm J., et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology 1990, 11:49-53.
66. Rolando N., Wade J., Davalos M., et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000, 32:734-739.
67. Tsai M.-H., Chen Y.-C., Lien J.-M., et al. Hemodynamics and metabolic studies on septic shock in patients with acute liver failure. J Crit Care 2008, 23:468-472.
68. Vaquero J., Polson J., Chung C., et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003, 125:755-764.
69. Rolando N., Gimson A., Wade J., et al. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology 1993, 17:196-201.
70. Rolando N., Wade J.J., Stangou A., et al. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. Liver Transpl Surg 1996, 2:8-13.
71. Salmeron J.M., Tito L., Rimola A., et al. Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. J Hepatol 1992, 14:280-285.
72. Schneeweiss B., Pammer J., Ratheiser K., et al. Energy metabolism in acute hepatic failure. Gastroenterology 1993, 105:1515-1521.
73. O'Beirne J., Holmes M., Agarwal B., et al. Adrenal insufficiency in liver disease-what is the evidence?. J Hepatol 2007, 47:418-423.
74. Lee W.M., Squires R.H., Nyberg S.L., et al. Acute liver failure: summary of a workshop. Hepatology 2008, 47:1401-1415.
75. Ring-Larsen H., Palazzo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut 1981, 22:585-591.
76. Davenport A., Will E.J., Davidson A.M. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993, 21:328-338.
77. Ellis A., Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis 1996, 16:379-388.
78. Wendon J.A., Harrison P.M., Keays R., et al. Effects of vasopressor agents and epoprostenol on systemic hemodynamics and oxygen transport in fulminant hepatic failure. Hepatology 1992, 15:1067-1071.
79. Larsen F.S., Strauss G., Knudsen G.M., et al. Cerebral perfusion, cardiac output, and arterial pressure in patients with fulminant hepatic failure. Crit Care Med 2000, 28:996-1000.
80. Shawcross D.L., Davies N.A., Mookerjee R.P., et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 2004, 39:471-475.
81. Eefsen M., Dethloff T., Frederiksen H.-J., et al. Comparison of terlipressin and noradrenalin on cerebral perfusion, intracranial pressure and cerebral extracellular concentrations of lactate and pyruvate in patients with acute liver failure in need of inotropic support. J Hepatol 2007, 47:381-386.
82. Baudouin S.V., Howdle P., O'Grady J.G., et al. Acute lung injury in fulminant hepatic failure following paracetamol poisoning. Thorax 1995, 50:399-402.
83. Bernard G.R., Artigas A., Brigham K.L., et al. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 1994, 20:225-232.
84. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 342:1301-1308. Anonymous.
85. Bonnet F., Richard C., Glaser P., et al. Changes in hepatic flow induced by continuous positive pressure ventilation in critically ill patients. Crit Care Med 1982, 10:703-705.
86. Prescott L.F., Illingworth R.N., Critchley J.A., et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J 1979, 2:1097-1100.
87. Brok J., Buckley N., Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2006, 2. CD003328.
88. Lauterburg B.H., Corcoran G.B., Mitchell J.R. Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest 1983, 71:980-991.
89. Saito C., Zwingmann C., Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 2010, 51:246-254.
90. Keays R., Harrison P.M., Wendon J.A., et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991, 303:1026-1029.
91. Harrison P.M., Wendon J.A., Gimson A.E., et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991, 324:1852-1857.
92. Sklar G.E., Subramaniam M. Acetylcysteine treatment for non-acetaminophen-induced acute liver failure. Ann Pharmacother 2004, 38:498-500.
93. Lee W.M., Hynan L.S., Rossaro L., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137:856-864.
94. Davern T.J., James L.P., Hinson J.A., et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006, 130:687-694.
95. Splendiani G., Tancredi M., Daniele M., et al. Treatment of acute liver failure with hemodetoxification techniques. Int J Artif Organs 1990, 13:370-374.
96. Ash S.R., Carr D.J., Sullivan T.A. Sorbent suspension reactor for extracorporeal detoxification in hepatic failure or drug overdose. ASAIO J 2004, 50:lviii-lxv.
97. Mitzner S.R., Stange J., Klammt S., et al. Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J 2009, 55:498-502.
98. O'Grady J.G., Gimson A.E., O'Brien C.J., et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988, 94:1186-1192.
99. Bihari D., Hughes R.D., Gimson A.E., et al. Effects of serial resin hemoperfusion in fulminant hepatic failure. Int J Artif Organs 1983, 6:299-302.
100. Stange J., Mitzner S.R., Risler T., et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999, 23:319-330.
101. Schmidt L.E., Wang L.P., Hansen B.A., et al. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003, 9:290-297.
102. Sen S., Rose C., Ytrebo L.M., et al. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study. Crit Care Med 2006, 34:158-164.
103. Camus C., Lavoue S., Gacouin A., et al. Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Therap Apher Dial 2009, 13:549-555.
104. Rifai K., Ernst T., Kretschmer U., et al. Prometheus-a new extracorporeal system for the treatment of liver failure. J Hepatol 2003, 39:984-990.
105. Oppert M., Rademacher S., Petrasch K., et al. Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit. Therap Apher Dial 2009, 13:426-430.
106. Wang Y., Susando T., Lei X., et al. Current development of bioreactors for extracorporeal bioartificial liver (review). Biointerphases 2010, 5:FA116-FA131.
107. Pless G. Bioartificial liver support systems. Methods Mol Biol 2010, 640:511-523.
108. Sharma R., Greenhough S., Medine C.N., et al. Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction. J Biomed Biotechnol 2010, 2010:236147.
109. Sussman N.L., Chong M.G., Koussayer T., et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992, 16:60-65.
110. Sussman N.L., Gislason G.T., Conlin C.A., et al. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994, 18:390-396.
111. Ellis A.J., Hughes R.D., Wendon J.A., et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996, 24:1446-1451.
112. Rozga J., Williams F., Ro M.S., et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993, 17:258-265.
113. Demetriou A.A., Brown R.S., Busuttil R.W., et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004, 239:660-667.
114. van de Kerkhove M.P., Di Florio E., Scuderi V., et al. Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs 2002, 25:950-959.
115. Mazariegos G.V., Kramer D.J., Lopez R.C., et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J 2001, 47:471-475.
116. Patzer J.F., Mazariegos G.V., Lopez R., et al. Preclinical evaluation of the Excorp Medical, Inc, Bioartificial Liver Support System. J Am Coll Surg 2002, 195:299-310.
117. Shakil A.O. Predicting the outcome of fulminant hepatic failure. Liver Transpl 2005, 11:1028-1030.
118. Park S.J., Lim Y.-S., Hwang S., et al. Emergency adult-to-adult living-donor liver transplantation for acute liver failure in a hepatitis B virus endemic area. Hepatology 2010, 51:903-911.
119. Faraj W., Dar F., Bartlett A., et al. Auxiliary liver transplantation for acute liver failure in children. Ann Surg 2010, 251:351-356.
120. Soltys K.A., Soto-Gutierrez A., Nagaya M., et al. Barriers to the successful treatment of liver disease by hepatocyte transplantation. J Hepatol 2010, 53:769-774.
121. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954.
122. Bilir B.M., Guinette D., Karrer F., et al. Hepatocyte transplantation in acute liver failure. Liver Transpl 2000, 6:32-40.
123. Mitry R.R., Dhawan A., Hughes R.D., et al. One liver, three recipients: segment IV from split-liver procedures as a source of hepatocytes for cell transplantation. Transplantation 2004, 77:1614-1616.
124. Hughes R.D., Mitry R.R., Dhawan A., et al. Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation. Liver Transpl 2006, 12:713-717.
125. Terry C., Dhawan A., Mitry R.R., et al. Optimization of the cryopreservation and thawing protocol for human hepatocytes for use in cell transplantation. Liver Transpl 2010, 16:229-237.
126. Stutchfield B.M., Forbes S.J., Wigmore S.J. Prospects for stem cell transplantation in the treatment of hepatic disease. Liver Transpl 2010, 16:827-836.